Diorasis Therapeutics

Diorasis Therapeutics is an early-stage biotech focused on transforming glaucoma treatment through gene therapy. Its lead candidate is designed to upregulate an enzymatically inactive tissue plasminogen activator (EI-tPA) in the eye's trabecular meshwork, aiming to normalize outflow facility and provide a potentially lifelong reduction in intraocular pressure after a single administration. The company operates in a large market with significant unmet need, as current glaucoma treatments require chronic dosing and have compliance issues. Diorasis is at the preclinical stage, building a team with expertise in ophthalmology and gene therapy to advance its innovative platform.

Gene therapy platform targeting the trabecular meshwork with an enzymatically inactive tissue plasminogen activator (EI-tPA) variant to remodel extracellular matrix and lower intraocular pressure.

Competition includes established pharmaceutical companies with eye drops (e.g., Allergan, Novartis), developers of sustained-release implants (e.g., Glaukos), and other gene therapy approaches targeting different pathways (e.g., neuroprotection, Schlemm's canal). Diorasis differentiates by directly targeting the trabecular meshwork's extracellular matrix with a gene-agnostic, potentially one-time therapy.